{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:53:16Z","timestamp":1791805996239,"version":"4.3.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K015346\/1"],"award-info":[{"award-number":["MR\/K015346\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K015346\/1"],"award-info":[{"award-number":["MR\/K015346\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007602","name":"DH | NIHR | Programme Grants for Applied Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIHR Senior Investigator"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Seropositivity for anti-citrullinated peptide antibodies (ACPA) in patients with rheumatoid arthritis (RA), a chronic autoimmune arthritis, is associated with worse long-term disease outcomes. ACPA is ubiquitously tested in RA patients, but other autoantibodies exist (in both citrullinated and non-citrullinated form) which may provide additional information on RA subtypes and\/or treatment response. We used a multiplex bead-based assay of 376 autoantibodies to test associations between these autoantibodies and treatment response in RA patients. Clusters of patients with similar autoantibody expression were defined and cluster membership was associated with treatment response. Thirty-four autoantibodies were differentially expressed in RA patients compared with healthy controls; citrullinated vimentin was associated with treatment response. A selection of citrullinated autoantibodies was found to be associated with treatment response in a subanalysis of ACPA-negative RA patients. Finer ACPA specificities in ACPA-negative RA patients may be predictive of treatment response and could represent a rich vein of future study.<\/jats:p>","DOI":"10.1038\/s41397-019-0139-4","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:05:35Z","timestamp":1575936335000},"page":"516-523","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients"],"prefix":"10.1038","volume":"20","author":[{"name":"MATURA consortium","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8148-2344","authenticated-orcid":false,"given":"Stephanie F.","family":"Ling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9829-792X","authenticated-orcid":false,"given":"Nisha","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M. M.","family":"Verstappen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3316-2527","authenticated-orcid":false,"given":"Anne","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Dieter","family":"Zucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schulz-Knappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Plant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"139_CR1","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N. Engl J Med. 2011;365:2205\u201319.","journal-title":"N. Engl J Med"},{"key":"139_CR2","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1136\/annrheumdis-2016-210602","volume":"76","author":"B Combe","year":"2017","unstructured":"Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Alvaro-Gracia JM, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2017;76:948\u201359.","journal-title":"Ann Rheum Dis"},{"key":"139_CR3","unstructured":"NICE. Rheumatoid arthritis in adults: management. 2018. https:\/\/www.nice.org.uk\/guidance\/ng100\/chapter\/Recommendations."},{"key":"139_CR4","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1136\/annrheumdis-2016-209991","volume":"76","author":"A van Zanten","year":"2017","unstructured":"van Zanten A, Arends S, Roozendaal C, Limburg PC, Maas F, Trouw LA, et al. Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands. Ann Rheum Dis. 2017;76:1184\u201390.","journal-title":"Ann Rheum Dis"},{"key":"139_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1155\/2013\/726598","volume":"35","author":"F Ingegnoli","year":"2013","unstructured":"Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical applications. Dis Markers. 2013;35:727\u201334.","journal-title":"Dis Markers"},{"key":"139_CR6","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/ard.2003.014233","volume":"63","author":"K Forslind","year":"2004","unstructured":"Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B, Group BS. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis. 2004;63:1090\u20135.","journal-title":"Ann Rheum Dis"},{"key":"139_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/ard.2007.084715","volume":"68","author":"C Potter","year":"2009","unstructured":"Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009;68:69\u201374.","journal-title":"Ann Rheum Dis"},{"key":"139_CR8","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/acr.20207","volume":"62","author":"TM Farragher","year":"2010","unstructured":"Farragher TM, Lunt M, Plant D, Bunn DK, Barton A, Symmons DP. Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies. Arthritis Care Res (Hoboken). 2010;62:664\u201375.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"139_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13075-018-1645-5","volume":"20","author":"JC Sergeant","year":"2018","unstructured":"Sergeant JC, Hyrich KL, Anderson J, Kopec-Harding K, Hope HF, Symmons DPM, et al. Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). Arthritis Res Ther. 2018;20:147.","journal-title":"Arthritis Res Ther"},{"key":"139_CR10","doi-asserted-by":"publisher","first-page":"17372","DOI":"10.1073\/pnas.1114465108","volume":"108","author":"J Shi","year":"2011","unstructured":"Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA. 2011;108:17372\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"139_CR11","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/j.1537-2995.2010.03022.x","volume":"51","author":"C Zoglmeier","year":"2011","unstructured":"Zoglmeier C, Martin S, Weinauer F. The Bavarian Red Cross Blood Donor BioBank: the first successful combination of blood donation and biobanking for medical research. Transfusion. 2011;51:1121\u20132.","journal-title":"Transfusion"},{"key":"139_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum"},{"key":"139_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van \u2018t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44\u20138.","journal-title":"Arthritis Rheum"},{"key":"139_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"AM van Gestel","year":"1996","unstructured":"van Gestel AM, Prevoo ML, van \u2018t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39:34\u201340.","journal-title":"Arthritis Rheum"},{"key":"139_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13075-016-1135-6","volume":"18","author":"S Vordenbaumen","year":"2016","unstructured":"Vordenbaumen S, Lueking A, Budde P, Zucht HD, Goehler H, Brinks R, et al. Sequential high-content profiling of the IgG-autoantibody repertoire reveals novel antigens in rheumatoid arthritis. Arthritis Res Ther. 2016;18:235.","journal-title":"Arthritis Res Ther"},{"key":"139_CR16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1177\/0961203316641770","volume":"25","author":"P Budde","year":"2016","unstructured":"Budde P, Zucht HD, Vordenbaumen S, Goehler H, Fischer-Betz R, Gamer M, et al. Multiparametric detection of autoantibodies in systemic lupus erythematosus. Lupus. 2016;25:812\u201322.","journal-title":"Lupus"},{"key":"139_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.molcel.2017.11.031","volume":"69","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Wang X, Forouzmand E, Jeong J, Qiao F, Sowd GA, et al. Molecular mechanisms for CFIm-mediated regulation of mRNA alternative polyadenylation. Mol Cell. 2018;69:62\u201374 e4.","journal-title":"Mol Cell"},{"key":"139_CR18","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1101\/gad.12.5.654","volume":"12","author":"Y Shi","year":"1998","unstructured":"Shi Y, Mosser DD, Morimoto RI. Molecular chaperones as HSF1-specific transcriptional repressors. Genes Dev. 1998;12:654\u201366.","journal-title":"Genes Dev"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0139-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0139-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-019-0139-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:00:15Z","timestamp":1684616415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-019-0139-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["139"],"URL":"https:\/\/doi.org\/10.1038\/s41397-019-0139-4","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,10]]},"assertion":[{"value":"26 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"PB and HDZ are employees of Oncimmune Germany GmbH, formerly Protagen AG. PSK is a previous employee and a shareholder of Protagen AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}